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Abstract
Background: Elevated triglyceride levels are a risk factor for cardiovascular disease. Angiopoietin-like protein 4
(Angptl4) is a metabolic factor that raises plasma triglyceride levels by inhibiting lipoprotein lipase (LPL). In non-
diabetic individuals, the ANGPTL4 coding variant E40K has been associated with lower plasma triglyceride levels
while the T266M variant has been associated with more modest effects on triglyceride metabolism. The objective
of this study was to determine whether ANGPTL4 E40K and T266M are associated with triglyceride levels in the
setting of obesity and T2D, and whether modification of triglyceride levels by these genetic variants is altered by a
lifestyle intervention designed to treat T2D.
Methods: The association of ANGPTL4 E40K and T266M with fasting triglyceride levels was investigated in 2,601
participants from the Look AHEAD Clinical Trial, all of whom had T2D and were at least overweight. Further, we
tested for an interaction between genotype and treatment effects on triglyceride levels.
Results: Among non-Hispanic White Look AHEAD participants, ANGPTL4 K40 carriers had mean triglyceride levels of
1.61 ± 0.62 mmol/L, 0.33 mmol/L lower than E40 homozygotes (p = 0.001). Individuals homozygous for the minor
M266 allele (MAF 30%) had triglyceride levels of 1.75 ± 0.58 mmol/L, 0.24 mmol/L lower than T266 homozygotes (p =
0.002). The association of the M266 with triglycerides remained significant even after removing K40 carriers from the
analysis (p = 0.002). There was no interaction between the weight loss intervention and genotype on triglyceride levels.
Conclusions: This is the first study to demonstrate that the ANGPTL4 E40K and T266M variants are associated with
lower triglyceride levels in the setting of T2D. In addition, our findings demonstrate that ANGPTL4 genotype status
does not alter triglyceride response to a lifestyle intervention in the Look AHEAD study.
Background
Studies in large Western [1] and Asian [2] population
cohorts have demonstrated an independent association
between elevated triglyceride levels and cardiovascular
disease (CVD) risk. Triglyceride levels may become ele-
vated through independent effects caused by the meta-
bolic syndrome and type 2 diabetes (T2D), both
well-established risk factors for CVD [3]. Furthermore,
lifestyle changes can significantly reduce triglyceride
levels [4] and may moderate the risk of CVD [5].
Lipoprotein lipase (LPL) regulates triglyceride levels by
hydrolyzing the triglyceride component of circulating
lipoproteins [6,7]. At least some of the effects of T2D
on triglycerides are mediated by LPL, whose expression
and activity is influenced by insulin [6,7]. The angio-
poietin-like protein 4 (Angptl4) peptide, which is pri-
marily expressed in the liver and white adipose tissue
[8], is another well established regulator of LPL activity
and triglyceride levels. In vitro studies confirm that
Angptl4, acting as an oligomer, inhibits enzymatic
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tion [9]. ANGPTL4 has two common coding SNPs:
E40K and T266M. The E40K substitution prevents
Angptl4 oligomer formation, which leads to reduced
Angptl4 mediated inhibition of LPL activity [10]. To
date, results in over 30,000 individuals from non-dia-
betic [11] and population-based [12] studies have con-
firmed that the E40K loss-of-function variant is
associated with significantly lower triglyceride levels
[11,12]. In contrast, the ANGPTL4 T266M cSNP, which
is more prevalent than E40K, has been shown to have a
smaller effect on triglyceride levels in non-diabetic
populations [12].
Given the importance of triglycerides and CVD risk in
the context of T2D we sought to determine whether the
ANGPTL4 E40K and T266M polymorphisms are asso-
ciated with triglyceride levels in well characterized patients
with T2D participating in the Look AHEAD study. Sec-
ond, we asked whether the ANGPTL4 variants modified
the triglyceride response to an intensive lifestyle interven-
tion designed to treat T2D that was randomly assigned to
Look AHEAD participants. Finding an association of
ANGPTL4 variants with triglyceride levels in T2D, parti-
cularly if modifiable by a lifestyle intervention, would have
important implications for personalized approaches to the
treatment of T2D and cardiovascular disease.
Methods
Look AHEAD (Action for Health in Diabetes)
Look AHEAD is a multicenter clinical trial examining
whether an intensive lifestyle intervention (ILI) aimed at
weight loss and increased activity will reduce cardiovas-
cular disease in T2D compared with diabetes support
and education (DSE). The Look AHEAD multi-ethnic
cohort is comprised of 5,145 male and female partici-
pants who have T2D, aged 45-76 years, and with a body
mass index (BMI) ≥ 25 kg/m
2. Included in our study are
samples from Look AHEAD participants who self-iden-
tified their race and ethnicity as non-Hispanic White,
African American or Hispanic. The design, baseline
characteristics, and 1-year interim results have been
described in detail [4,13,14]. This manuscript is based
on a subset of the baseline data set from participants
who provided consent for genetic studies and were
enrolled from Look AHEAD sites that participated in
ancillary studies (see Acknowledgement). 2,601 partici-
pants for whom DNA was available for these analyses,
were genotyped for ANGPTL4 T266M (rs1044250, 6959
C > T) and E40K (rs116843064, 118 G > A) cSNPs
using TaqMan technology (Applied Biosciences). All
participants provided written informed consent for DNA
collection and genetic studies as part of Look AHEAD.
The Tufts Medical Center Institutional Review Board
approved the study.
Statistical Methods
Statistical analyses were performed using Intercooled
Stata 10.2 for Windows (StataCorp LP, Texas, USA). A
c
2 test compared whether the observed frequencies con-
formed to Hardy-Weinberg equilibrium (HWE). A gen-
eral additive model of inheritance, or dominant model
in the case of E40K, was used to assess the association
between genotype and clinical endpoints. All clinical
data were log transformed to approximate a normal dis-
tribution before analysis. Multivariate linear regressions
were used for baseline association analyses, controlling
for known and significant confounders including: age,
gender, study site, BMI, smoking, statins, diuretics, dia-
betes drugs, insulin, other lipid drugs, alcohol, meno-
pause, and hormone replacement therapy (HRT) use.
Using a dominant model there was 80% power to detect
a 0.08 mmol/L difference in triglycerides between E40K
allele carriers and non-carriers at baseline. Using an
additive model there was 80% power to detect a differ-
ence at baseline of 0.02 mmol/L in triglyceride levels
per T266M allele. Both power calculations are based on
a 2-sided test at 5% significance level.
Multivariate linear regression was also utilized to
determine interaction of DSE and ILI with E40K and
T266M genotype. Additional association analyses per-
formed at the 1-year follow-up time point were adjusted
for age, gender, study site and the baseline measure of
the dependent variable. P values < 0.05 were considered
significant. Linkage disequilibrium (LD) between sites
was estimated using Haploview (http://www.broad.mit.
edu/mpg/haploview) version 3.0.
Results
ANGPTL4: effects on plasma Triglyceride and HDL levels
in Look AHEAD
Baseline characteristics of the Look AHEAD study parti-
cipants included in these analyses, separated by ethnic
groups, are shown in Table 1. Of the 2,601 study parti-
cipants, 1,424 are taking lipid lowering medication.
ANGPTL4 genotype frequences are shown in Table 2.
All genotype distributions were in HWE. No LD was
observed between E40K and T266M in non-Hispanic
White Americans (D’ =1 . 0 0a n dr
2 = 0.05). The MAF
for the E40K and T266M variants did not differ signifi-
cantly between non-Hispanic Whites and Hispanics.
The MAF of the E40K SNP in African Americans by
comparison was very low (MAF 0.001).
After adjustment for covariates, the E40K variant was
significantly associated with baseline plasma triglyceride
levels in non-Hispanic White Look AHEAD participants
(Table 3). Individuals who were K40 carriers had mean
± SD triglyceride levels of 1.61 ± 0.62 mmol/L, 0.33
mmol/L lower than E40 homozygotes (p = 0.001). A sig-
nificant association of the T266M and triglyceride levels
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the M266 allele had triglyceride levels of 1.75 ± 0.58
mmol/L, 0.24 mmol/L lower than T266 homozygotes (p
= 0.002). The association of E40K and T266M with tri-
glyceride levels remained significant in those individuals
not taking a lipid lowering medication (Tables 3 and 4,
respectively). The association of E40K with triglyceride
levels was also significant in subjects taking lipid lower-
ing drugs, while the triglyceride association with T266M
was not found in the setting of lipid lowering therapy
(data not shown).
We examined whether the association of T266M with
triglyceride levels merely reflected the presence of E40K
or whether the effect was also observed independently.
When the K40 carriers were excluded, the association of
T266M with triglycerides remained significant in multi-
variate linear regression using an additive model of
inheritance, with M266 homozygotes having 0.25 mmol/
L lower triglycerides compared to TT individuals (p =
0.002) (Table 4).
Next, we analyzed participants by composite E40K and
T266M genotypes. We found a significant genotype
dosage effect in which the addition of K40 to M266 was
associated with lower triglyceride levels suggesting an
additive effect in the Look AHEAD cohort (Figure 1).
Homozygous M266 carriers that were also heterozygous
K40 carriers had the lowest triglyceride levels.
Secondary analyses of traits related to the metabolic
syndrome detected a significant association of E40K
with systolic blood pressure (4.24 mm/Hg lower in K40
carriers; p = 0.031) (Table 3) and a modest association
with waist circumference (p = 0.043). Only triglyceride
levels showed significant differences by T266M genotype
(Table 4).
We were unable to test an association of E40K and tri-
glycerides in African American and Hispanic Look
Table 1 Baseline Data in Look AHEAD Genetic cohort by ethnic group
Variable Non-Hispanic white Americans African American Hispanics P value*
n Mean 95% CI N Mean 95% CI n Mean 95% CI
Female (%) 2023 50.2 - 436 76.6 - 142 64.8 -
Insulin Use (%) 2023 17.0 - 436 22.9 - 142 19.7 -
Statin Use (%) 2023 50.1 - 436 37.6 - 142 38.0 -
Metabolic Syndrome (%) 2023 95.4 - 436 76.6 - 142 64.8 -
Hypertension (%) 2023 84.9 - 436 89.5 - 142 81.0 -
Age (years) 2023 59.47 (59.17, 59.77) 436 58.40 (57.97, 58.83) 142 57.32 (56.46, 58.19) < 0.001
HbA1c (%) 2023 7.17 (7.12, 7.21) 436 7.34 (7.27, 7.41) 142 7.52 (7.38, 7.66) < 0.001
Weight (lbs) 2023 223.85 (222.28, 255.44) 436 220.83 (218.54, 223.14) 142 217.85 (213.36, 222.43) 0.021
BMI (kg/m2) 2023 35.88 (35.65, 36.11) 436 35.93 (35.58, 36.29) 142 35.99 (35.29, 36.70) 0.790
Waist circumference (cm) 2020 114.98 (114.42, 115.55) 436 113.17 (112.34, 114.00) 142 111.38 (109.77, 113.01) < 0.001
Triglyceride (mmol/L) 2023 1.87 (1.82, 019) 436 1.57 (1.52, 1.62) 142 1.32 (1.23, 1.41) < 0.001
LDL-cholesterol (mmol/L) 1975 2.77 (2.74, 2.80) 427 2.80 (2.75, 2.86) 138 2.84 (2.73, 2.94) 0.269
HDL-cholesterol (mmol/L) 1975 1.06 (1.05, 1.07) 427 1.11 (1.09, 1.13) 138 1.16 (1.13, 1.20) < 0.001
Cholesterol (mmol/L) 1975 4.85 (4.81, 4.89) 427 4.81 (4.75, 4.87) 138 4.77 (4.66, 4.89) 0.242
Fasting Glucose (mmol/L) 1975 8.32 (8.22, 8.42) 427 8.09 (7.95, 8.24) 138 7.88 (7.60, 8.16) 0.007
SBP (mm/Hg) 1993 128.82 (128.06, 129.58) 432 129.52 (128.39, 130.66) 140 130.23 (127.98, 132.52) 0.268
DBP (mm/Hg) 1993 69.41 (69.03, 69.80) 432 70.98 (70.4, 71.57) 140 72.59 (71.41, 73.79) < 0.001
Data presented is mean (95% confidence intervals), adjusted for age and gender;* overall comparison between the three ethnic groups after adjustment for
gender.
Table 2 Look AHEAD genotype frequencies of ANGPTL4 E40K and T266M by ethnic group
ANGPTL4 variant Genotype Non-Hispanic White Americans African American Hispanic P value
n % MAF n % MAF n % MAF p1 p2 p3
E40K 118 G > A
EE GG 1868 95.8 418 99.8 129 95.6
EK/KK GA/AA 82/0 4.2 0.021 1/0 0.2 0.001 5/1 4.4 0.027 < 0.001 0.551 < 0.001
T266M rs1044250
TT CC 961 48.1 242 56.0 63 45.0
TM CT 845 42.2 164 34.0 61 43.6
MM TT 194 9.7 0.31 26 6.0 0.25 16 11.4 0.33 < 0.001 0.403 0.007
p1; Non-Hispanic whites vs. African Americans, p2; Non-Hispanic whites vs. Hispanics, p3; African Americans vs. Hispanics.
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carriers (Additional File 1: Supplemental Tables 1 and 2).
One year follow-up data in non-Hispanic white Americans
Look AHEAD participants in this genetic sub-cohort
randomly assigned to DSE achieved a 1% reduction of
BMI compared with an 11% reduction in the ILI group
(p < 0.001). The response to DSE and ILI in the Look
AHEAD participants taking part in these genetic studies
was similar to the one-year differences observed in the
full cohort [4]. Triglyceride levels decreased in both ran-
domisation groups, with subjects in the ILI group
achieving 27% lower levels compared with 9% lower
levels in the DSE group. Tests for interaction between
intervention and E40K and T266M status were not sta-
tistically significant (p = 0.416 and 0.202 respectively).
The absolute changes in triglyceride levels were similar
between E40K and T266M genotypes (Additional File 1:
Supplemental Tables 3 and 4).
Discussion
In this study, we demonstrate for the first time that
ANGPTL4 E40K and T266M are associated with trigly-
ceride levels in the setting of T2D. This finding is
Table 3 Association of E40K with baseline data in Non-Hispanic White Look AHEAD participants
EE EK P value
Mean (95% CI) Mean (95% CI)
n males/n females 934/934 40/42 -
Triglycerides (mmol/L) 1.94 (1.90, 1.99) 1.61 (1.44, 1.80) 0.001
Cholesterol (mmol/L) 4.86 (4.82, 4.90) 4.88 (4.69, 5.08) 0.889
LDL-cholesterol (mmol/L) 2.77 (2.73, 2.80) 2.87 (2.70, 3.04) 0.237
HDL-cholesterol (mmol/L) 1.05 (1.04, 1.06) 1.10 (1.05, 1.16) 0.081
BMI (kg/m
2) 35.90 (35.87, 35.93) 35.91 (35.78, 36.03) 0.940
Weight (kg) 100.55 (100.21, 100.90) 101.51 (99.88, 103.17) 0.264
Waist Circumference (cm) 115.03 (114.69, 115.37) 116.73 (115.11, 118.37) 0.043
Glucose (mmol/L) 8.38 (8.28, 8.49) 8.02 (7.56, 8.51) 0.154
HbA1c 7.18 (7.14, 7.23) 7.00 (6.79, 7.22) 0.113
SBP (mm/Hg) 129.12 (128.31, 129.93) 124.88 (121.23, 128.64) 0.031
DBP (mm/Hg) 69.38 (68.98, 69.79) 67.55 (65.71, 69.43) 0.062
Triglycerides (mmol/L) on subjects not receiving lipid lowering medication 1.91 (1.85, 1.98)
(n = 771)
1.54 (1.31, 1.80)
(n = 36)
0.007
Data presented is mean (95% confidence intervals). Lipid data and blood pressure are adjusted for age, gender, study site, BMI, smoking, statins, diuretics,
diabetes drugs, insulin, other lipid drugs, alcohol, menopause, HRT use. Anthropometric data are adjusted for age, gender, study site, smoking, statins, diuretics,
diabetes drugs, insulin, other lipid drugs, alcohol, menopause, HRT use. Adjusted P values using a dominant model of inheritance are presented.
Table 4 Association of T266M with baseline data in Non-Hispanic White Look AHEAD participants
TT TM MM P value
Mean (95% CI) Mean (95% CI) Mean (95% CI)
n males/n females 461/500 428/417 93/101 -
Triglycerides (mmol/L) 1.99 (1.93, 2.06) 1.87 (1.81, 1.94) 1.75 (1.63, 1.89) 0.002
Cholesterol (mmol/L) 4.91 (4.85, 4.96) 4.84 (4.78, 4.90) 4.79 (4.66, 4.91) 0.120
LDL-cholesterol (mmol/L) 2.78 (2.73, 2.82) 2.77 (2.72, 2.83) 2.75 (2.65, 2.86) 0.937
HDL-cholesterol (mmol/L) 1.05 (1.04, 1.07) 1.05 (1.05, 1.12) 1.09 (1.05, 1.12) 0.178
BMI (kg/m
2) 35.94 (35.90, 35.97) 35.89 (35.85, 35.93) 35.97 (35.89, 36.05) 0.101
Weight (lbs) 100.71 (100.22, 101.19) 100.31 (99.80, 100.83) 101.10 (100.03, 102.18) 0.331
Waist Circumference (cm) 115.08 (114.61, 115.55) 114.91 (114.40, 115.41) 115.77 (114.72, 116.82) 0.346
Glucose (mmol/L) 8.44 (8.30, 8.59) 8.32 (8.17, 8.47) 8.19 (7.89, 8.51) 0.269
HbA1c 7.22 (7.16, 7.29) 7.13 (7.02, 7.20) 7.08 (6.95, 7.23) 0.067
SBP (mm/Hg) 129.18 (128.06, 130.30) 128.68 (127.48, 129.88) 126.85 (124.41, 129.34) 0.243
DBP (mm/Hg) 69.45 (68.89, 70.01) 69.15 (68.55, 69.76) 68.43 (67.20, 69.68) 0.327
Triglyceride (mmol/L)
Following removal of E40K Carriers
1.99 (1.92, 2.06)
(n = 889)
1.88 (1.81, 1.95)
(n = 775)
1.73 (1.60, 1.88)
(n = 182)
0.002
Triglycerides (mmol/L)
Subjects not taking lipid-lowering medication
1.95 (1.86, 2.05)
(n = 416)
1.82 (1.74, 1.93)
(n = 344)
1.66 (1.48, 1.85)
(n = 75)
0.01
Data presented is mean (95% confidence intervals). Lipid data and blood pressure are adjusted for age, gender, study site, BMI, smoking, statins, diuretics,
diabetes drugs, insulin, other lipid drugs, alcohol, menopause, HRT use. Anthropometric data are adjusted for age, gender, study site, smoking, statins, diuretics,
diabetes drugs, insulin, other lipid drugs, alcohol, menopause, HRT use. Adjusted P values using an additive model of inheritance are presented.
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E40 homozygotes and T266 carriers may contribute to
an increased risk of CVD in the setting of T2D. Non-
Hispanic White Look AHEAD K40 carriers had 17%
lower triglyceride levels than non-K40 carriers, which is
a similar effect as reported in studies in the general
population [11,12]. We therefore conclude that the
effect of the ANGPTL4 E40K polymorphism is unlikely
diminished to any substantial degree by the independent
effects of obesity and T2D on triglyceride levels. The
lack of interaction with treatment indicates that there is
no differential effect of genotypes on triglycerides
depending upon randomization to ILI versus DSE. This
final point demonstrates the potential role of a life-style
intervention to reduce triglyceride levels conferred by
genetic background [15].
We identified an association of triglyceride levels with
ANGPTL4 T266M that appeared to be independent of,
and potentially additive with, the E40K variant. The
T266M triglyceride effect is consistent with the Eur-
opean Atherosclerosis Research Study II CHD offspring
study which demonstrated that M266 homozygotes had
enhanced triglyceride clearance following an oral fat tol-
erance test [12]. Our results contrast to the findings of
Talmud et al [12], who reported a similar pattern of
linkage disequilibrium between the two cSNPs, but
found the association of T266M with triglycerides to be
dependent on the K40 allele. The observation that the
triglyceride-lowering effect of T266M is not lost after
removal of K40 carriers in Look AHEAD suggests that
the T266M cSNP may have an independent effect on
triglycerides in the setting of T2D. The fact that the
association of T266M with triglyceride levels was not
observed in Look AHEAD participants receiving lipid
lowering medication, but maintained on those not on
medications, suggests that an important interaction
between medications and T266M may exist. Alterna-
tively, the reduced sample size in this sub-group analysis
may have reduced our power to detect an association.
E40K carriers in ARIC and the Copenhagen City
Heart Study had significantly higher HDL-cholesterol
levels than non-carriers, while the Dallas Heart Study
did not confirm this relationship [11]. While a mechan-
istic link between plasma triglycerides and HDL-choles-
terol mediated by the cholesterol ester transfer protein
is well established [16], large differences in triglycerides
are typically required before a significant change in
HDL-cholesterol is found. We detected a modest, albeit
non-significant, elevation of HDL-cholesterol in K40
carriers. Other factors that regulate HDL-cholesterol
levels (e.g. insulin resistance, obesity) may have wea-
kened the effect of E40K.
Both the E40 (within the N-terminus) and the T266
(within the C-terminus) amino acid residues are con-
served across human, mouse and rat species [17] sug-
gesting functional importance. Formation of Angptl4
oligomers by disulphide bonds in the coiled-coil N-ter-
minus [17] is required for inhibition of LPL activity.
The E40K substitution destabilizes the protein after
secretion, preventing the extracellular accumulation of
oligomers and abolishing the ability of the Angptl4 pro-
tein to inhibit LPL activity [10]. By comparison, the
mechanism by which T266M alters the function of the
C-terminal fibrinogen domain remains undefined.
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Figure 1 Mean triglyceride levels in Non-Hispanic White Americans from Look AHEAD by Composite ANGPTL4 E40K and T266M
genotype. Triglyceride data are adjusted for age, gender, study site, BMI, smoking, statins, diuretics, diabetes drugs, insulin, other lipid drugs,
alcohol, menopause, HRT use; P value comparing mean triglycerides to the reference EE/TT composite genotype carriers; * indicates P < 0.05 and
** indicates P < 0.01. No Look AHEAD participant was found to carry the composite EK/TT genotype.
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ymous mutations throughout ANGPTL4, including the
fibrinogen domain, compromise the ability of Angptl4
to inhibit LPL activity.
A limitation of the study is the low number of African
American and Hispanic ANGPTL4 variant carriers. Sta-
tistically this resulted in underpowered association stu-
dies which prevented the examination of E40K in African
Americans. The ANGPTL4 variant frequencies for Hispa-
nics were comparable to Non-Hispanic White Americans
(0.027 and 0.021). The low total number of Hispanics (n
= 137) and E40K carriers (n = 6) reduced our power to
detect an association. While we included anti-diabetic
medication use as a covariate in our analyses an addi-
tional limitation is that we were unable to control for the
effect of specific anti-diabetic medications and doses,
which may have an effect on triglyceride levels.
Conclusion
In conclusion, we demonstrate for the first time an asso-
ciation of the ANGPTL4 coding variants with triglyceride
levels in the setting of T2D. Further, our results suggest
that the triglyceride response to a lifestyle intervention is
not altered by ANGPTL4 genotype status. This finding
broadens our understanding of the role of Angptl4 in
regulation of LPL metabolism of triglycerides. The inde-
pendent association of T266M with triglycerides has
broad implications because this polymorphism has a high
frequency in the general population.
Additional material
Additional file 1: Supplemental Analysis of ANGPTL4 E40K and
T266M Genotype Status in Look AHEAD. This additional file includes
four supplemental data tables. The first two tables describe the
association analysis findings of ANGPTL4 E40K (Table S1) and T266M
(Table S2) with baseline biochemical and anthropometric baseline levels
in African American and Hispanic Look AHEAD participants. The
remaining two tables describe the association analysis findings of
ANGPTL4 E40K (Table S3) and T266M (Table S4) with absolute change in
baseline biochemical and anthropometric measurements to year 1
follow-up in Non-Hispanic White Look AHEAD participants.
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